Revenue
2024
XTL BIOPHARMACEUTICALS LTD (XTLB)
Price—Loading quote
Net income
2016
2017
2018
2019
2020
2021
2022
2024
Free cash flow
2015
2016
2019
2020
2024
Total cash / debt
CashTotal debt
2016
2017
2018
2019
2020
2021
2022
2024
Financial statements
| 2024 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $451,000 | — | — | — | — | — | — | — | — |
| Gross profit | $3,000 | — | — | — | — | — | — | — | — |
| Research & development | $98,000 | $30,000 | $30,000 | $38,000 | $35,000 | $38,000 | $43,000 | $443,000 | $578,000 |
| Operating income | −$2.2M | −$880,000 | −$1.0M | −$948,000 | −$842,000 | −$793,000 | −$1.2M | −$2.6M | −$3.6M |
| EBITDAderived | −$1.8M | — | — | — | — | — | −$1.2M | −$2.6M | −$3.6M |
| Net income | −$1.0M | −$1.3M | $435,000 | −$3.0M | −$763,000 | $3.6M | −$781,000 | −$2.5M | $2,000 |
| Basic EPSper diluted share | -$0.00 | -$0.00 | $0.00 | -$0.01 | -$0.00 | $0.01 | -$0.00 | -$0.01 | -$0.02 |
| Diluted EPSper diluted share | -$0.00 | -$0.00 | $0.00 | -$0.01 | -$0.00 | $0.01 | -$0.00 | -$0.01 | -$0.02 |